Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACRX is in the long-term down -65% below S&P in 10 years.
Description: AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP);
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.04||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||154.93%||Sales Growth - Q/Q||-19.91%||P/E||-2.31|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-44.64%||ROE||-82.14%||ROI||-58.1%|
|Current Ratio||4.26||Quick Ratio||Long Term Debt/Equity||0.32||Debt Ratio||0.37|
|Gross Margin||Operating Margin||-763.87%||Net Profit Margin||-636.39%||Dividend Payout Ratio|
|Cash From Financing Activities||370 K||Cash From Investing Activities||-510 K||Cash From Operating Activities||-10.75 M||Gross Profit|
|Net Profit||-10.03 M||Operating Profit||-11.4 M||Total Assets||75.59 M||Total Current Assets||65.42 M|
|Total Current Liabilities||15.36 M||Total Debt||25.14 M||Total Liabilities||34.51 M||Total Revenue||180 K|
|High 52 week||5.5||Low 52 week||1.7||Last close||3.65||Last change||-1.35%|
|RSI||77.78||Average true range||0.2||Beta||0.78||Volume||150.74 K|
|Simple moving average 20 days||12.39%||Simple moving average 50 days||34.74%||Simple moving average 200 days||46.59%|
|Performance Week||8.96%||Performance Month||46%||Performance Quart||71.76%||Performance Half||69.77%|
|Performance Year||63.68%||Performance Year-to-date||80.25%||Volatility daily||3.96%||Volatility weekly||8.87%|
|Volatility monthly||18.17%||Volatility yearly||62.94%||Relative Volume||149.89%||Average Volume||522.21 K|
|New High||New Low|
2020-06-01 20:00:00 | AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
2020-05-29 08:30:00 | AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
2020-05-27 11:54:35 | Hedge Funds Have Never Been Less Bullish On AcelRx Pharmaceuticals Inc ACRX
2020-05-27 09:54:00 | AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
2020-05-12 15:20:30 | Edited Transcript of ACRX earnings conference call or presentation 11-May-20 8:30pm GMT
2020-05-12 03:00:49 | AcelRx Pharmaceuticals Inc ACRX Q1 2020 Earnings Call Transcript
2020-05-11 18:45:10 | AcelRx Pharmaceuticals ACRX Reports Q1 Loss, Misses Revenue Estimates
2020-05-11 16:01:00 | AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-05-08 12:00:04 | All You Need to Know About AcelRx Pharmaceuticals ACRX Rating Upgrade to Buy
2020-05-08 09:09:01 | Is a Beat in Store for Sunoco SUN This Earnings Season?
2020-05-07 12:55:11 | Bidding War Sends Tetraphase Shares Soaring
2020-05-06 12:30:04 | AcelRx Pharmaceuticals ACRX Expected to Beat Earnings Estimates: Should You Buy?
2020-05-05 12:51:04 | Tetraphase TTPH to Post Q1 Earnings: What's in the Cards?
2020-05-02 08:08:29 | One Thing To Remember About The AcelRx Pharmaceuticals, Inc. NASDAQ:ACRX Share Price
2020-04-30 06:00:00 | AcelRx Announces DSUVIA® Milestone C Approval and Provides Business Update
2020-04-24 06:11:10 | Bet on Rising P/E Investing With These Top 5 Stocks
2020-04-23 09:09:01 | AcelRx's Shares March Higher, Can It Continue?
2020-04-16 12:02:06 | 3 Compelling Penny Stocks With at Least 50% Upside Potential
2020-04-02 12:28:04 | The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
2020-04-01 08:18:12 | After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
2020-03-27 12:00:04 | All You Need to Know About AcelRx Pharmaceuticals ACRX Rating Upgrade to Buy
2020-03-18 06:05:01 | AcelRx Pharmaceuticals, Inc. Just Reported, And Analysts Assigned A US$6.40 Price Target
2020-03-17 17:50:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tetraphase Pharmaceuticals, Inc. with AcelRx Pharmaceuticals, Inc. is Fair to TTPH Shareholders
2020-03-17 13:47:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Tetraphase Pharmaceuticals, Inc.
2020-03-17 03:23:34 | Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT
2020-03-16 09:02:11 | AcelRx Pharmaceuticals: Q4 Earnings Insights
2020-03-16 07:35:00 | AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-16 07:30:00 | AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals
2020-03-11 19:50:00 | AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020
2020-03-10 14:25:00 | AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April
2020-02-27 12:30:05 | Earnings Preview: AcelRx Pharmaceuticals ACRX Q4 Earnings Expected to Decline
2020-02-24 10:28:03 | AcelRx ACRX to Report Q4 Earnings: What's in the Cards?
2020-02-07 06:49:26 | Should You Worry About AcelRx Pharmaceuticals, Inc.'s NASDAQ:ACRX CEO Salary Level?
2020-01-27 17:45:10 | AcelRx Pharmaceuticals ACRX Stock Moves -1.14%: What You Should Know
2020-01-13 17:50:10 | AcelRx Pharmaceuticals ACRX Stock Sinks As Market Gains: What You Should Know
2020-01-13 07:00:00 | AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates
2020-01-07 10:21:03 | Soleno SLNO Ends Enrollment in Prader-Willi Syndrome Study
2020-01-07 09:51:02 | Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates
2020-01-06 06:38:11 | Have Faith in Rising P/E: Play 5 Top-Ranked Stocks
2020-01-03 12:00:05 | AcelRx Pharmaceuticals ACRX Upgraded to Strong Buy: What Does It Mean for the Stock?
2020-01-03 09:07:02 | Top Ranked Momentum Stocks to Buy for January 3rd
2019-12-31 11:05:04 | Jazz Enrolls First Patient in Phase II/III Leukemia Study